New Delhi: 2nd April 2013
“The court has recognised the right of patients to access affordable medicines over profits for big pharma companies”. It was celebration time for health activists and civil society groups after the Supreme Court delivered its judgment dismissing Swiss multinational company Novartis’ appeal for patent for its anti-cancer medicine imatinib mesylate or Gleevec.
Read more
“The court has recognised the right of patients to access affordable medicines over profits for big pharma companies”. It was celebration time for health activists and civil society groups after the Supreme Court delivered its judgment dismissing Swiss multinational company Novartis’ appeal for patent for its anti-cancer medicine imatinib mesylate or Gleevec.
Read more
RSS Feed
